Ulcerative colitis.

@article{Danese2011UlcerativeC,
  title={Ulcerative colitis.},
  author={Silvio Danese and Claudio Fiocchi},
  journal={The New England journal of medicine},
  year={2011},
  volume={365 18},
  pages={
          1713-25
        }
}
 Is medical clearance required? .................................. Possibly (e.g., if the disease is unstable — flare-up — and/or there are active oral lesions). Also, medical clearance may be required if patient/client is being treated with medications associated with immunosuppression +/increased risk of infection (e.g., corticosteroids [e.g., prednisone], azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, sulfasalazine, biologic response modifier drugs [e.g., anti-tumour necrosis… 

Figures and Tables from this paper

Biological Agents for Moderately to Severely Active Ulcerative Colitis

A systematic review of randomized, controlled trials assessing biological agents as induction or maintenance therapy for moderately to severely active UC in adults to address this issue and compare the different treatment options.

Positioning therapies in ulcerative colitis.

  • S. DaneseG. FiorinoL. Peyrin-Biroulet
  • Biology, Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2020

TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.

A patient with active ulcerative colitis with primary non-response to three biologics, with different mechanisms of action, who refused surgical treatment and had a favorable response to tofacitinib with clinical and endoscopic remission is reported.

Immunosuppressive and biologic therapy for ulcerative colitis

There is a need for optimizing and renewing the traditional therapeutic approach to UC, and new therapies beyond conventional treatment options possibly aiming to change the poor clinical course of many patients with ulcerative colitis.

Inflammatory bowel disease and targeted oral anti-TNFα therapy.

Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges

Data is summarized regarding AJM300, phosphatidylcholine (LT-02), mongersen, ozanimod, filgotinib and tofacitinib, which were tested in clinical trials for both Crohn’s disease and ulcerative colitis.

Ulcerative Colitis.

Inflammatory pathways of importance for management of inflammatory bowel disease.

The major signaling pathways of clinical importance for IBD therapy are elucidated and several new treatment options are under development for the treatment of CD and UC, however, no drug fits all patients.

Ulcerative Colitis: Update on Medical Management

The recent publication of the SCENIC consensus statement on surveillance and management of Dysplasia in UC patients supports the use of chromoendoscopy over random biopsies in detecting dysplasia and new biologics, including those targeting the Janus tyrosine kinase (JAK) pathway are on the horizon to add to the current armamentarium of anti-TNF alpha and anti-integrin therapies.

Skin Manifestations of Inflammatory Bowel Disease

Current knowledge on cutaneous EIMs, their diagnostic criteria and clinical presentation, natural history, pathogenesis, and treatment options are summarized.
...

References

SHOWING 1-10 OF 104 REFERENCES

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?

Preliminary evidence suggests that a substantial proportion of patients in clinical remission for >1 year, without signs of active inflammation can remain in remission after stopping treatment, and there are insufficient data to make recommendations on when to stop anti-TNF therapy.

Exacerbation of ulcerative colitis after rituximab salvage therapy

The data suggest an important anti‐ rather than proinflammatory role of B‐cells in UC, which is in contrast to rheumatoid arthritis patients, rituximab had deleterious effects in this UC patient by blocking IL‐10 producing B‐ cells.

Biological therapies for inflammatory bowel diseases.

Infliximab, a chimeric immunoglobulin (Ig)G1 monoclonal antibody to tumor necrosis factor, dramatically improved treatment of patients with Crohn's disease and ulcerative colitis and has achieved treatment goals such as mucosal healing and decreasing the need for hospitalizations and surgeries.

Diagnostic Standards in the Pathology of Inflammatory Bowel Disease

A high degree of awareness by clinicians and pathologists is required in order to miss these life-threatening complications of IBD, and the use of modern immunosuppressive therapies may go along with an increased susceptibility towards infections.

Colectomy rate in acute severe ulcerative colitis in the infliximab era.

  • A. AratariC. Papi R. Caprilli
  • Medicine
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2008

Update on the etiology, pathogenesis and diagnosis of ulcerative colitis

  • S. Hanauer
  • Medicine
    Nature Clinical Practice Gastroenterology &Hepatology
  • 2004
The diagnosis of ulcerative colitis is being aided by recent advances in diagnostic strategies, including the detection of fecal and serologic markers and the use of wireless capsule endoscopy, but, in the absence of a pathognomonic marker, the definition of this disease remains undefined.

Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production

The data provide a proof-of-concept that IL-13 is an effector cytokine in ulcerative colitis and should be a target for novel therapies.
...